Stockreport

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Tenth Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s ENHERTU with the latest based on DESTINY-Breast05 phase 3 trial resultsSixteenth Breakthrough [Read more]